Companies: 10,795·Total market cap: $144.5T
MapLight Therapeutics, Inc.

MapLight Therapeutics, Inc.

MPLTNASDAQHealthcare● Active
$30.05
+$0.59(+1.99%)
Market Cap$23717239
P/E Ratio
52W High$33.28
52W Low$12.24

MapLight Therapeutics, Inc.(MPLT)股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

mplt · 股价预测 · 2 位分析师(近3月)· FMP · 更新于 2026年6月9日

分析师评级与共识

基于过去 3 个月内 2 位华尔街分析师

SellBuy

Buy

2 位分析师

共识

评级分布

Strong Buy
0
Buy
2
Hold
0
Sell
0
Strong Sell
0
合计: 2 · 买入占比: 100.0%

12 个月目标价

High

$48.00

Consensus

$43.00

+46.0% upside

Low

$36.00

Median: $44 · Last Close: $29.46

MapLight Therapeutics, Inc.(MPLT)的分析师共识为 Buy,基于过去 3 个月内 2 位华尔街分析师的评级。MPLT 的 12 个月平均目标价为 $43.00,相对当前价 $29.46 代表 +46.0% 的潜在上行空间。

12 个月目标价预测

历史收盘价 + 分析师 12 个月目标价预测区间

Historical priceConsensus $43 (46.0%)

Consensus Target

$43.00

46.0% upside

High Target

$48

62.9%

Low Target

$36

22.2%

Current Price

$29.46

as of today

Based on analyst price targets, the MPLT stock price prediction for the next 12 months ranges from $36 to $48. The consensus MPLT price forecast of $43.00 implies 46.0% upside from the current price of $29.46.

短期股价预测

Bull

算法生成 · 每日更新

DatePredicted PriceChange
2026-06-10$29.121.16%

1-day model range: $28.88–$29.36. Peak: $29.36 (-1.16%).

长期股价预测

⚠️ 在满 252 个交易日历史(IPO/上市时间较短)前不展示长期预测;短期标签页仍可能显示模型输出。

基于技术分析的股价预测

14 项技术面信号(SMA×6 + EMA×6 + RSI + MACD)· EEAT 方法论透明

Market Sentiment

BULLISH

Based on 14 technical indicators

79%21%0%
11Buy
3Neutral
0Sell
RSI (14)60.6Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · MPLT · Jun 9, 2026

Simple Moving Average (SMA)
MA 5$28.65BUY
MA 10$29.11BUY
MA 20$28.98BUY
MA 50$27.76BUY
MA 100$22.83BUY
MA 200$0.00NEUTRAL
Current $MPLT · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$28.98BUY
EMA 10$28.95BUY
EMA 20$28.84BUY
EMA 50$27.11BUY
EMA 100$24.24BUY
EMA 200$0.00NEUTRAL
Current $MPLT · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:
Stifel2026-06-02
Maintains
BuyBuy
HC Wainwright & Co.2026-05-28
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on MapLight Therapeutics, Inc. (MPLT) stock. Of the recent 2 rating actions, 0 were upgrades and 0 were downgrades. 2 analysts currently cover MPLT.

分析师推荐趋势

Buy ratings11
Hold ratings00
Sell ratings00

MPLT analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

财务预测:EPS 与营收一致预期

Revenue This Year

$0M

Revenue Next Year

$0M

EPS This Year

$-4.93

EPS Next Year

$-4.26

↓ 13.5% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast MPLT EPS of $-4.93 for the current fiscal year, based on estimates from 7 analysts. The MPLT revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

MPLT 股价预测由两类独立数据源支撑:来自 2 位华尔街分析师(S&P Global / FMP)的共识评级,以及基于历史日终价计算的技术分析。MPLT 的共识目标价为 $43.00(+46.0% 上行空间),分析师共识为 Buy。

MPLT 的短期预测(明日)为 $29.12(-1.16%)。

MapLight Therapeutics, Inc. 在 NASDAQ 上市,代码 MPLT。MPLT 在 2027 年的整体展望偏积极,在覆盖分析师中约 100% 对应 Buy 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

常见问题

MPLT 预测 · 8 个问题

根据 2 位华尔街分析师,MPLT 的 12 个月平均目标价为 $43.00,最高 $48.00、最低 $36.00。若有图表,中位目标价可在上方查看。相对当前价 $29.46,隐含约 +46.0% 的上行空间。

MPLT 目标价MPLT 分析师目标价MPLT 12个月目标价目标价 MPLT

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.